DiaMedica Therapeutics (DMAC) Change in Account Payables (2018 - 2026)

DiaMedica Therapeutics (DMAC) has reported Change in Account Payables for 9 consecutive years, with -$481000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Change in Account Payables fell 95.53% year-over-year to -$481000.0; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 208.96% YoY), and the FY2025 full-year result was $535000.0, up 3721.43% from the prior year.
• Change in Account Payables declined to -$481000.0 in Q2 2026 per DMAC's latest filing, from $1.8 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $1.8 million in Q1 2026 and bottomed at -$924000.0 in Q2 2023.
• Historically, Change in Account Payables has averaged $127944.4 across 5 years, with a median of $25000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Change in Account Payables surged 5785.71% in 2024, then slumped 672.09% in 2025.
• Over 5 years, Change in Account Payables stood at -$130000.0 in 2022, then soared by 148.46% to $63000.0 in 2023, then slumped by 466.67% to -$231000.0 in 2024, then sank by 92.64% to -$445000.0 in 2025, then retreated by 8.09% to -$481000.0 in 2026.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$481000.0, $1.8 million, and -$445000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.